MYCN and neoplasm: Looking into a very narrow lens for characterizing only MYCN and ALK copy numbers, we found in this small study cohort that ALK gain of 4 copies in patient (ID Rec1) with available whole genome sequencing and high-depth targeted sequencing of synchronous tumor samples showed no changes to ALK copy number.